53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
08.10.2024
Treatment of chronic cough remains a challenge. It was hypothesised that inhaled alkaline hypertonic divalent salts (alkaline HDS) might provide relief for refractory chronic cough by laryngeal and tracheal hydration.
We conducted an exploratory, single-blinded, nasal saline-controlled study in 12 refractory chronic cough patients to examine cough suppression efficacy of an alkaline HDS composition (SC001) at pH 8 or pH 9 administered by nasal inhalation. As control, we used nasal saline with the same hand-held pump spray aerosol device. Each subject was monitored continuously using a Hyfe CoughMonitor Suite's watch (older version than available in 2024) for 1 week of baseline, 1 week of control treatment and 1 week of active treatment.
Baseline daily cough rates ranged from 4 to 34 coughs·h−1 with mean visual analogue score 65±17 pre- and post-baseline testing. Control-adjusted efficacy of cough rate reduction ranged from 15% (p=0.015) (from Day 1) to 23% (p=0.002) (from Day 3). Control-adjusted efficacy was highest with SC001 pH 9 (n=5), ranging from 25% (p=0.03) (from Day 1) to 35% (p=0.02) (from Day 3), and lowest for SC001 pH 8 (n=7), ranging from 9% (p=0.08) (from Day 1) to 16% (p=0.02) (from Day 3). Hourly cough counts and visual analogue score correlated for baseline (r=0.254, p=0.02) and control (r=0.299, p=0.007) monitoring weeks. Treatment improved this correlation (r=0.434, p=0.00006). No adverse events were reported.
Alkaline (pH 9) HDS aerosol is a promising treatment for refractory chronic cough and should be further evaluated.
